Cell signaling pathways as molecular targets to eliminate AML stem cells

Ana Carolina B da C Rodrigues; Rafaela G A Costa; Suellen L R Silva; Ingrid R S B Dias; Rosane B Dias; Daniel P Bezerra

doi:10.1016/j.critrevonc.2021.103277

Cell signaling pathways as molecular targets to eliminate AML stem cells

Crit Rev Oncol Hematol. 2021 Apr:160:103277. doi: 10.1016/j.critrevonc.2021.103277. Epub 2021 Mar 11.

Authors

Ana Carolina B da C Rodrigues¹, Rafaela G A Costa¹, Suellen L R Silva¹, Ingrid R S B Dias¹, Rosane B Dias¹, Daniel P Bezerra²

Affiliations

¹ Gonçalo Moniz Institute, Oswaldo Cruz Foundation (IGM-FIOCRUZ/BA), Salvador, Bahia, 40296-710, Brazil.
² Gonçalo Moniz Institute, Oswaldo Cruz Foundation (IGM-FIOCRUZ/BA), Salvador, Bahia, 40296-710, Brazil. Electronic address: daniel.bezerra@fiocruz.br.

PMID: 33716201
DOI: 10.1016/j.critrevonc.2021.103277

Abstract

Acute myeloid leukemia (AML) remains the most lethal of leukemias and a small population of cells called leukemic stem cells (LSCs) has been associated with disease relapses. Some cell signaling pathways play an important role in AML survival, proliferation and self-renewal properties and are abnormally activated or suppressed in LSCs. This includes the NF-κB, Wnt/β-catenin, Hedgehog, Notch, EGFR, JAK/STAT, PI3K/AKT/mTOR, TGF/SMAD and PPAR pathways. This review aimed to discuss these pathways as molecular targets for eliminating AML LSCs. Herein, inhibitors/activators of these pathways were summarized as a potential new anti-AML therapy capable of eliminating LSCs to guide future researches. The clinical use of cell signaling pathways data can be useful to enhance the anti-AML therapy.

Keywords: Acute myeloid leukemia; Cell signaling; Leukemic stem cells; Target therapy.

Publication types

Review

MeSH terms

Humans
Leukemia, Myeloid, Acute* / drug therapy
Leukemia, Myeloid, Acute* / genetics
NF-kappa B / metabolism
Neoplastic Stem Cells* / metabolism
Phosphatidylinositol 3-Kinases
Signal Transduction

Substances

NF-kappa B